We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Expert Opinion / Commentary · December 06, 2022

2022 Top Story in Dermatology: Is Melanoma Overdiagnosed?

Written by
Jane Grant-Kels MD


Additional Info

  1. Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med. 2021;384(1):72-79.
  2. Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158(5):495-503.
  3. Olsen CM, Whiteman DC. Cutaneous Melanoma in White Americans: A Tale of 2 Epidemics. J Invest Dermatol. 2022;142(7):1765-1767.
  4. Grossman D, Sweeney C, Doherty JA. The Rapid Rise in Cutaneous Melanoma Diagnoses. N Engl J Med. 2021;384(14):e54.
  5. Paiva ML, Weinstock MA. Melanoma Overdiagnosis Is Not the Key Problem. JAMA Dermatol. 2022;158(9):1082-1083.
  6. Chen ML, de Vere Hunt IJ, John EM, et al. Differences in thickness-specific incidence and factors associated with cutaneous melanoma in the US from 2010 to 2018. JAMA Oncol. 2022;8(5):755-759.
  7. Muzumdar S, Lin G, Kerr P, et al. Evidence concerning the accusation that melanoma is overdiagnosed. J Am Acad Dermatol. 2021;85(4):841-846.
  8. Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol. 2006;19(2):S34–S40.
  9. Shoo BA, Sagebiel RW, Kashani-Sabet M. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol. 2010;62(5):751-756.
  10. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35(5):433-444.
  11. Kerr KF, Eguchi MM, Piepkorn MW, et al. Dermatopathologist Perceptions of Overdiagnosis of Melanocytic Skin Lesions and Association With Diagnostic Behaviors. JAMA Dermatol. 2022;158(6):675-679.
  12. Helsing P, Loeb M. Small diameter melanoma: a follow‐up of the Norwegian Melanoma Project. Br J Dermatol. 2004;151(5):1081-1083.
  13. Liu R, Pugliano-Mauro M, Patton T, et al. Re-evaluating the ABCD criteria using a consecutive series of melanomas. J Am Acad Dermatol. 2020;83(4):1161-1163.
  14. Goldsmith SM. The Rapid Rise in Cutaneous Melanoma Diagnoses. N Engl J Med. 2021;384(14):e54.
  15. Argenziano G, Cerroni L, Zalaudek I, et al. Accuracy in melanoma detection: A 10-year multicenter survey. J Am Acad Dermatol. 2012;67(1):54-59.
  16. Whiteman DC, Olsen CM, MacGregor S, et al.The effect of screening on melanoma incidence and biopsy rates. Br J Dermatol. 2022;187(4):515-522.
  17. Matsumoto M, Wack S, Weinstock MA, et al. Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. JAMA Dermatol. 2022;158(5):504-512.
  18. Kulkarni RP, Yu WY, Leachman SA. To Improve Melanoma Outcomes, Focus on Risk Stratification, Not Overdiagnosis. JAMA Dermatol. 2022;158(5):485-487.

Disclosure statements are available on the authors' profiles:

Further Reading